What Is Takayasu's Arteritis? Arteritis is a general term that refers to the inflammation of arteries — blood vessels that carry blood away from the heart and to the rest of the body.

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

Giant cell arteritis is a systemic vasculitis and careful attention should be given to the examination of the cardiovascular system including performing blood pressure measurements in both arms.

Researchers have discovered in a new study that glucocorticoid-induced adrenal insufficiency (GIAI) was rare (1.9%) in ...

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an ...

The European Commission (EC) has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg ...

Glucocorticoid-induced adrenal insufficiency was lower in prevalence than previously estimated among patients with PMR or GCA.

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...